OmniAb, Inc.
Financials
Valuation Metrics
OmniAb, Inc.'s Market Cap is $648M. At end of 2025 it was $236M. Ranked #2690 of 3,121 in US market (top 86%), #1157 of 1,463 on NASDAQ (top 79%), #212 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 80%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $648M | US#2,690/3,121 Sec#212/266 |
| Revenue | $38M | US#2,789/3,121 Sec#155/266 |
| Net Income | $-44M | US—/3,121 Sec—/266 |
| Total Assets | $290M | US#2,920/3,121 Sec#211/266 |
| Net Assets | $260M | US#2,584/3,121 Sec#166/266 |
| Employees | 89 | US#2,653/3,121 Sec#187/266 |
| Value | ||
| P/B | 2.49x | US#1,526/3,121 Sec#68/266 |
| P/S | 16.86x | US#2,818/3,121 Sec#138/266 |
| FCF Yield | -2.80% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -17.01% | US#2,461/3,121 Sec#94/266 |
| ROA | -15.25% | US#2,751/3,121 Sec#118/266 |
| Op. Margin | -125.80% | US#2,750/3,121 Sec#128/266 |
| Revenue Growth | 66.89% | US#158/3,121 Sec#42/266 |
| Financial Health | ||
| Debt Ratio | 11.52% | US#127/3,121 Sec#56/266 |
| Total Debt | $19M | US#2,768/3,121 Sec#192/266 |
| FCF | $-18M | US#2,415/3,121 Sec#93/266 |
| Cash | $24M | US#2,820/3,121 Sec#253/266 |
| Current Ratio | 4.80x | US#499/3,121 Sec#150/266 |
| Performance | ||
| 1Y Return | 169.28% | US#82/3,121 Sec#30/266 |
| 1M Return | 6.68% | US#171/3,121 Sec#21/266 |
| From 52W High | -17.68% | US#1,372/3,121 Sec#95/266 |
| 1Y MDD | -37.04% | US#1,862/3,121 Sec#128/266 |
| Trading | ||
| Volume | 1,642,178 shares | US#1,415/3,121 Sec#152/266 |
| Trading Value | $7M | US#2,718/3,121 Sec#230/266 |
| Per Share | ||
| EPS | $-0.31 | US—/3,121 Sec—/266 |
| BPS | $1.80 | US#2,594/3,121 Sec#183/266 |
Company Info
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.